Iovance Biotherapeutics, Inc.
IOVA
$6.98
$0.467.06%
NASDAQ
Recommendation
Dividend Power Score
Prev Close
Volume
Avg Vol (90D)
Market Cap
Dividend & Yield
--
P/E (TTM)
--
EPS (TTM)
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 324.97M | 285.61M | 263.50M | 250.43M | 241.53M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 324.97M | 285.61M | 263.50M | 250.43M | 241.53M |
| Cost of Revenue | 167.68M | 172.97M | 173.18M | 167.86M | 160.90M |
| Gross Profit | 157.29M | 112.64M | 90.32M | 82.56M | 80.62M |
| SG&A Expenses | 149.18M | 147.47M | 152.32M | 158.24M | 163.02M |
| Depreciation & Amortization | 36.56M | 36.41M | 35.94M | 35.58M | 36.30M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 621.14M | 643.64M | 661.72M | 661.75M | 652.16M |
| Operating Income | -296.17M | -358.04M | -398.21M | -411.33M | -410.64M |
| Income Before Tax | -293.78M | -354.76M | -393.05M | -398.33M | -389.73M |
| Income Tax Expenses | -4.26M | -898.00K | -2.07M | -697.00K | 188.00K |
| Earnings from Continuing Operations | -289.52 | -353.86 | -390.98 | -397.63 | -389.92 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -289.52M | -353.86M | -390.98M | -397.63M | -389.92M |
| EBIT | -296.17M | -358.04M | -398.21M | -411.33M | -410.64M |
| EBITDA | -259.44M | -321.46M | -362.12M | -371.16M | -371.67M |
| EPS Basic | -0.72 | -0.95 | -1.12 | -1.20 | -1.23 |
| Normalized Basic EPS | -0.45 | -0.59 | -0.70 | -0.76 | -0.79 |
| EPS Diluted | -0.72 | -0.95 | -1.12 | -1.20 | -1.23 |
| Normalized Diluted EPS | -0.45 | -0.59 | -0.70 | -0.76 | -0.79 |
| Average Basic Shares Outstanding | 1.64B | 1.52B | 1.43B | 1.33B | 1.27B |
| Average Diluted Shares Outstanding | 1.64B | 1.52B | 1.43B | 1.33B | 1.27B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |